Abhishek Jaiswal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Abhishek Jaiswal has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- David A. Baran
Cleveland Clinic Florida, Weston, Florida, USA
7 shared publications - William Leslie Baker
University of Connecticut School of Pharmacy Storrs Connecticut USA
7 shared publications - Ashwin Pillai
University of Connecticut School of Medicine
6 shared publications Zeina Jedeon
Hartford Healthcare Heart and Vascular Institute
6 shared publicationsWilliam L. Baker
University of Connecticut School of Pharmacy, Department of Pharmacy Practice, Storrs, CT
5 shared publicationsBalaphanidhar Mogga
Frank H Netter School of Medicine/Quinnipiac University
4 shared publications
Latest Publications
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1290-1305
International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1290-1305
International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
- Open Access
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e043588
Short‐Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States
Background: Heart transplant (HT) and left ventricular assist devices (LVADs) are treatment options for advanced heart failure refractory to standard therapy. Historically, LVADs have been used as either destination therapy or a bridge to transplant. However, recent changes to the organ allocation system have deprioritized patients on LVADs as transplant recipients, leading to divisive views on the role of an LVAD. The comparative short‐term care burden with each modality remains unclear. Methods: We aimed to describe and compare characteristics, outcomes, and cost burden during index hospitalizations and 30‐day and 90‐day readmissions associated with HTs and durable LVADs from a large, national administrative database. A review of the Nationwide Readmissions Database from 2018 to 2021 describing a cohort identified using International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ) procedure codes: 02YA0Z0 and 02HA0QZ. Results: We identified 27 308 index hospital admissions; 52.4% received LVADs, and the remainder received HTs. Compared with HT recipients, LVAD recipients were older and more likely male, of lower socioeconomic status, had longer index hospital stays, and had more expensive index hospitalizations. A higher proportion of LVAD recipients required rehospitalization in 30 days. The most frequent causes of rehospitalization in the LVAD group at both 30 and 90 days were heart failure, device complications, and gastrointestinal bleeding. The most frequent causes in the HT group at 30 and 90 days were transplant complications, renal dysfunction, and sepsis (at 90 days only). Thirty‐ and 90‐day rehospitalization costs were greater in the HT group. Conclusions: Both LVAD and HT had comparable burdens on resources and short‐term rehospitalization risk.
- 3 March 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (5) , e043588
Open AccessShort‐Term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States
Background: Heart transplant (HT) and left ventricular assist devices (LVADs) are treatment options for advanced heart failure refractory to standard therapy. Historically, LVADs have been used as either destination therapy or a bridge to transplant. However, recent changes to the organ allocation system have deprioritized patients on LVADs as transplant recipients, leading to divisive views on the role of an LVAD. The comparative short‐term care burden with each modality remains unclear. Methods: We aimed to describe and compare characteristics, outcomes, and cost burden during index hospitalizations and 30‐day and 90‐day readmissions associated with HTs and durable LVADs from a large, national administrative database. A review of the Nationwide Readmissions Database from 2018 to 2021 describing a cohort identified using International Classification of Diseases, Tenth Revision, Clinical Modification ( ICD‐10‐CM ) procedure codes: 02YA0Z0 and 02HA0QZ. Results: We identified 27 308 index hospital admissions; 52.4% received LVADs, and the remainder received HTs. Compared with HT recipients, LVAD recipients were older and more likely male, of lower socioeconomic status, had longer index hospital stays, and had more expensive index hospitalizations. A higher proportion of LVAD recipients required rehospitalization in 30 days. The most frequent causes of rehospitalization in the LVAD group at both 30 and 90 days were heart failure, device complications, and gastrointestinal bleeding. The most frequent causes in the HT group at 30 and 90 days were transplant complications, renal dysfunction, and sepsis (at 90 days only). Thirty‐ and 90‐day rehospitalization costs were greater in the HT group. Conclusions: Both LVAD and HT had comparable burdens on resources and short‐term rehospitalization risk.
- 6 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (1) , e70430
Safety and Efficacy of Apixaban in HeartMate 3 Left Ventricular Assist Devices
Background: Warfarin, the anticoagulant of choice for durable left ventricular assist devices (LVADs), has a narrow therapeutic index and extensive pharmacologic interactions that make dose optimization challenging. Inadequate time in the therapeutic range increases the risk of thrombotic and hemorrhagic complications. We sought to evaluate the safety and efficacy of apixaban as an alternative anticoagulant for HeartMate (HM) 3 LVADs. Methods: We analyzed data for patients with HM3 LVADs treated at our center between 2018 and 2024, comparing thromboembolic and hemorrhagic events between patients receiving warfarin and those who transitioned to apixaban due to adverse events or labile therapeutic responses on warfarin. Results: We included 47 patients, 16 of whom remained on warfarin, while 31 transitioned to apixaban. Both cohorts had identical baseline characteristics. Rates of all‐cause bleeding per 100 patient‐years were similar for warfarin (33) and apixaban (29), p = 0.24. The relative risk (RR) of major bleeding within the first 3 months of anticoagulation was significantly lower with apixaban—RR 0.08 (95% CI, 0.01–0.65, p = 0.01), with an incidence rate of 6.4% on apixaban versus 43.8% on warfarin. All‐cause bleeding occurred less frequently with apixaban at 32% compared to 68.8%—RR 0.14 (95% CI 0.03–0.62, p = 0.009). Hemocompatibility improved in the apixaban group, evidenced by an increase in hemoglobin (11 ± 2 to 12 ± 2 g/dL, p < 0.001) and a decrease in lactate dehydrogenase (427 ± 129 to 221 ± 83 U/L, p < 0.001). Thrombotic events were identical. Conclusion: In patients with HM3 LVADs, apixaban may be a safe and clinically effective alternative to warfarin.
- 6 January 2026
- Published by Wiley in Clinical Transplantation
- Vol. 40 (1) , e70430
Safety and Efficacy of Apixaban in HeartMate 3 Left Ventricular Assist Devices
Background: Warfarin, the anticoagulant of choice for durable left ventricular assist devices (LVADs), has a narrow therapeutic index and extensive pharmacologic interactions that make dose optimization challenging. Inadequate time in the therapeutic range increases the risk of thrombotic and hemorrhagic complications. We sought to evaluate the safety and efficacy of apixaban as an alternative anticoagulant for HeartMate (HM) 3 LVADs. Methods: We analyzed data for patients with HM3 LVADs treated at our center between 2018 and 2024, comparing thromboembolic and hemorrhagic events between patients receiving warfarin and those who transitioned to apixaban due to adverse events or labile therapeutic responses on warfarin. Results: We included 47 patients, 16 of whom remained on warfarin, while 31 transitioned to apixaban. Both cohorts had identical baseline characteristics. Rates of all‐cause bleeding per 100 patient‐years were similar for warfarin (33) and apixaban (29), p = 0.24. The relative risk (RR) of major bleeding within the first 3 months of anticoagulation was significantly lower with apixaban—RR 0.08 (95% CI, 0.01–0.65, p = 0.01), with an incidence rate of 6.4% on apixaban versus 43.8% on warfarin. All‐cause bleeding occurred less frequently with apixaban at 32% compared to 68.8%—RR 0.14 (95% CI 0.03–0.62, p = 0.009). Hemocompatibility improved in the apixaban group, evidenced by an increase in hemoglobin (11 ± 2 to 12 ± 2 g/dL, p < 0.001) and a decrease in lactate dehydrogenase (427 ± 129 to 221 ± 83 U/L, p < 0.001). Thrombotic events were identical. Conclusion: In patients with HM3 LVADs, apixaban may be a safe and clinically effective alternative to warfarin.
- Open Access
Bridging Adults to Heart Transplant: Temporary versus Durable Mechanical Circulatory Support and Post-Transplant Outcomes
Background: The current United States donor heart allocation system prioritizes patients receiving temporary mechanical circulatory support over those with durable left ventricular assist devices (d-LVADs), but the impact on post-transplant survival remains unclear. Objectives: To evaluate post-transplant outcomes in patients bridged with d-LVAD versus t-LVAD before and after the 2018 United Network for Organ Sharing (UNOS) allocation policy change. Methods: Using the UNOS database, we analyzed 24,795 adult first-time HT recipients from 2011–2023, stratified by device type at transplant: d-LVAD (43.3%), t-LVAD (6.4%), or no LVAD. Outcomes included survival at 30 days, 90 days, 1 year, and 2 years. Risk-adjusted analyses were performed using Cox proportional hazards models. Subgroup analysis examined time on LVAD and the impact of organ preservation on outcomes. Results: Compared to t-LVAD and no-LVAD recipients, d-LVAD recipients had significantly higher adjusted mortality rates at all time points (hazard ratios ranged from 1.44 at 30 days to 1.18 at 2 years; p < 0.001). The mortality gap was more pronounced under the current allocation era. In patients with device duration data, ≥2 years on LVAD was associated with a 39% higher 1-year mortality risk (HR 1.39, 95% CI 1.15–1.68). No significant differences in 1-year mortality were observed between DCD donor and machine-perfused donor transplant subgroups by LVAD status. Conclusions: Post-transplant survival is worse with d-LVAD bridging, particularly under current allocation rules, and prolonged LVAD support further elevates risk. These findings underscore the need to reevaluate LVAD strategy and transplant prioritization, considering evolving allocation policies. Condensed In a UNOS analysis of 24,795 heart transplants (2011–2023), patients bridged with durable LVADs (43.3%) consistently experienced worse post-transplant survival than those with temporary LVADs (6.4%) or no device. Adjusted mortality was higher at all time points (HR 1.44 at 30 days to 1.18 at 2 years; p<0.001), with disparities becoming more pronounced after the 2018 allocation change. Prolonged LVAD use (≥2 years) further increased the risk. These findings highlight the need to reevaluate durable LVAD strategies and transplant prioritization. Preprint Server: None
Open AccessBridging Adults to Heart Transplant: Temporary versus Durable Mechanical Circulatory Support and Post-Transplant Outcomes
Background: The current United States donor heart allocation system prioritizes patients receiving temporary mechanical circulatory support over those with durable left ventricular assist devices (d-LVADs), but the impact on post-transplant survival remains unclear. Objectives: To evaluate post-transplant outcomes in patients bridged with d-LVAD versus t-LVAD before and after the 2018 United Network for Organ Sharing (UNOS) allocation policy change. Methods: Using the UNOS database, we analyzed 24,795 adult first-time HT recipients from 2011–2023, stratified by device type at transplant: d-LVAD (43.3%), t-LVAD (6.4%), or no LVAD. Outcomes included survival at 30 days, 90 days, 1 year, and 2 years. Risk-adjusted analyses were performed using Cox proportional hazards models. Subgroup analysis examined time on LVAD and the impact of organ preservation on outcomes. Results: Compared to t-LVAD and no-LVAD recipients, d-LVAD recipients had significantly higher adjusted mortality rates at all time points (hazard ratios ranged from 1.44 at 30 days to 1.18 at 2 years; p < 0.001). The mortality gap was more pronounced under the current allocation era. In patients with device duration data, ≥2 years on LVAD was associated with a 39% higher 1-year mortality risk (HR 1.39, 95% CI 1.15–1.68). No significant differences in 1-year mortality were observed between DCD donor and machine-perfused donor transplant subgroups by LVAD status. Conclusions: Post-transplant survival is worse with d-LVAD bridging, particularly under current allocation rules, and prolonged LVAD support further elevates risk. These findings underscore the need to reevaluate LVAD strategy and transplant prioritization, considering evolving allocation policies. Condensed In a UNOS analysis of 24,795 heart transplants (2011–2023), patients bridged with durable LVADs (43.3%) consistently experienced worse post-transplant survival than those with temporary LVADs (6.4%) or no device. Adjusted mortality was higher at all time points (HR 1.44 at 30 days to 1.18 at 2 years; p<0.001), with disparities becoming more pronounced after the 2018 allocation change. Prolonged LVAD use (≥2 years) further increased the risk. These findings highlight the need to reevaluate durable LVAD strategies and transplant prioritization. Preprint Server: None
- 11 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (1)
Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1‐Year After Adult Heart Transplant
Objective: To use machine learning methods to identify factors associated with corticosteroid (CS) discontinuation 1 year after adult heart transplantation (HT). Design: Retrospective, observational, cohort study. Data Source: This study used data from the United Network for Organ Sharing (UNOS) database. Patients: We included adults (age ≥ 18 years) who underwent their first HT between January 2000 and December 2023 in the UNOS database with follow‐up through December 2024, who were discharged on a CS. Measurements: We divided the cohort into those with or without CS at 1‐year post‐transplant follow‐up. We used the eXtreme Gradient Boosting (XGBoost) algorithm to build a model predicting CS discontinuation at 1 year. Relevant recipient, donor, and transplant variables were included to train the model, with Shapley Additive Explanations (SHAP) used to identify and interpret the most important and predictive features. Results: We identified 72,730 HT recipients; 13,017 (17.9%) had CS discontinued within the first year. Compared with the CS cessation group, those who continued CS were more likely to have had a lower BMI, lower ischemic etiology of cardiomyopathy, lower intra‐aortic balloon pump (IABP) and left ventricular assist device (LVAD) use before HT, better renal function, and sustained longer donor ischemic time. Model performance was strong, with an area under the curve of 0.854 (95% confidence interval: 0.848–0.861). Lower average transplant center volume (number of transplants per year), shorter donor ischemic time, and LVAD use at transplant predicted CS discontinuation. Conclusions: In a large national database, utilizing novel ML modeling techniques, we identified annual transplant center volume, donor ischemia time, and LVAD use at the time of HT as the best predictors of CS discontinuation 1 year after HT.
- 11 November 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (1)
Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1‐Year After Adult Heart Transplant
Objective: To use machine learning methods to identify factors associated with corticosteroid (CS) discontinuation 1 year after adult heart transplantation (HT). Design: Retrospective, observational, cohort study. Data Source: This study used data from the United Network for Organ Sharing (UNOS) database. Patients: We included adults (age ≥ 18 years) who underwent their first HT between January 2000 and December 2023 in the UNOS database with follow‐up through December 2024, who were discharged on a CS. Measurements: We divided the cohort into those with or without CS at 1‐year post‐transplant follow‐up. We used the eXtreme Gradient Boosting (XGBoost) algorithm to build a model predicting CS discontinuation at 1 year. Relevant recipient, donor, and transplant variables were included to train the model, with Shapley Additive Explanations (SHAP) used to identify and interpret the most important and predictive features. Results: We identified 72,730 HT recipients; 13,017 (17.9%) had CS discontinued within the first year. Compared with the CS cessation group, those who continued CS were more likely to have had a lower BMI, lower ischemic etiology of cardiomyopathy, lower intra‐aortic balloon pump (IABP) and left ventricular assist device (LVAD) use before HT, better renal function, and sustained longer donor ischemic time. Model performance was strong, with an area under the curve of 0.854 (95% confidence interval: 0.848–0.861). Lower average transplant center volume (number of transplants per year), shorter donor ischemic time, and LVAD use at transplant predicted CS discontinuation. Conclusions: In a large national database, utilizing novel ML modeling techniques, we identified annual transplant center volume, donor ischemia time, and LVAD use at the time of HT as the best predictors of CS discontinuation 1 year after HT.
- 4 September 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (2) , 310-323
Biomarker-Based Surveillance in Heart Transplant Rejection
- 4 September 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 42 (2) , 310-323
Biomarker-Based Surveillance in Heart Transplant Rejection
- 26 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (9) , 1526
Re: Optimizing the handling of missing data in the UNOS database
- 26 May 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (9) , 1526
Re: Optimizing the handling of missing data in the UNOS database
- Open Access
Short-term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States
Background Heart transplant (HT) and left ventricular assist devices (LVADs) are treatment options for advanced heart failure refractory to standard therapy. Historically, LVADs have been used as either destination therapy or a bridge to transplant. However, recent changes to the organ allocation system have deprioritized patients on LVADs as transplant recipients, leading to divisive views on the role of an LVAD. Comparative short term care burden with each modality remains unclear. Objectives To describe and compare characteristics, outcomes and cost burden during index hospitalizations, 30-day and 90-day readmissions associated with heart transplants (HT) and durable left ventricular assist devices (LVAD) from a large, national administrative database. Methods A review of the Nationwide Readmissions Database (NRD) from 2018-2021 describing a cohort identified using ICD-10-CM procedure codes: 02YA0Z0 and 02HA0QZ. Results We identified 27,308 index hospital admissions; 52.4% received LVADs and the remainder received HT. Compared to HT recipients LVAD recipients were older and more likely male, of lower socio-economic status, had longer index hospital stays, and more expensive index hospitalizations. A higher proportion of LVAD recipients required rehospitalizations in 30 days. The most frequent causes of re-hospitalization in the LVAD group at both 30 and 90 days were heart failure, device complications, and gastrointestinal bleeding. The most frequent causes in the HT group at 30 and 90 days were transplant complications, renal dysfunction, and sepsis (at 90 days only). 30 and 90-day rehospitalization costs were greater in the HT group. Conclusions Both LVAD and HT had comparable burdens on resource and short-term rehospitalization risk.
Open AccessShort-term Care Burden After Left Ventricular Assist Device Implantation and Heart Transplant in the United States
Background Heart transplant (HT) and left ventricular assist devices (LVADs) are treatment options for advanced heart failure refractory to standard therapy. Historically, LVADs have been used as either destination therapy or a bridge to transplant. However, recent changes to the organ allocation system have deprioritized patients on LVADs as transplant recipients, leading to divisive views on the role of an LVAD. Comparative short term care burden with each modality remains unclear. Objectives To describe and compare characteristics, outcomes and cost burden during index hospitalizations, 30-day and 90-day readmissions associated with heart transplants (HT) and durable left ventricular assist devices (LVAD) from a large, national administrative database. Methods A review of the Nationwide Readmissions Database (NRD) from 2018-2021 describing a cohort identified using ICD-10-CM procedure codes: 02YA0Z0 and 02HA0QZ. Results We identified 27,308 index hospital admissions; 52.4% received LVADs and the remainder received HT. Compared to HT recipients LVAD recipients were older and more likely male, of lower socio-economic status, had longer index hospital stays, and more expensive index hospitalizations. A higher proportion of LVAD recipients required rehospitalizations in 30 days. The most frequent causes of re-hospitalization in the LVAD group at both 30 and 90 days were heart failure, device complications, and gastrointestinal bleeding. The most frequent causes in the HT group at 30 and 90 days were transplant complications, renal dysfunction, and sepsis (at 90 days only). 30 and 90-day rehospitalization costs were greater in the HT group. Conclusions Both LVAD and HT had comparable burdens on resource and short-term rehospitalization risk.
- 16 November 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 420, 132747
Donor pulmonary hemodynamics does not impact recipient outcomes in adult heart transplantation.
- 16 November 2024
- Published by Elsevier in International Journal of Cardiology
- Vol. 420, 132747
Donor pulmonary hemodynamics does not impact recipient outcomes in adult heart transplantation.